Acta Pharmaceutica Sinica. B最新文献_第2页

Microneedle-based delivery for autoimmune diseases: Emerging opportunities and unresolved questions 基于微针的自身免疫性疾病递送：新出现的机会和未解决的问题

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-04-01 Epub Date: 2026-04-17 DOI: 10.1016/j.apsb.2026.03.042

Jiamin Wu

引用次数: 0

Fluorescence bioimaging of drug nanocarriers based on Förster resonance energy transfer, aggregation-induced emission and aggregation-caused quenching 基于Förster共振能量转移、聚集致发射和聚集致猝灭的药物纳米载体荧光生物成像

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-04-01 Epub Date: 2025-10-27 DOI: 10.1016/j.apsb.2025.10.023

Runtong Zhang , Haisheng He , Yi Lu , Aun Raza , Wei Wu

引用次数: 0

A spatiotemporal selective bioinspired hybrid system engineered for preventing post-thrombolysis recurrence by inhibiting the ferroptosis pathway and reprogramming macrophages 一个时空选择性生物激发的混合系统，通过抑制铁凋亡途径和巨噬细胞重编程来预防溶栓后复发

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-04-01 Epub Date: 2026-01-22 DOI: 10.1016/j.apsb.2026.01.014

Tianjiao Hao , Bin Gao , Yuanyuan Zhou , Chang Liu , Chuanjiang Ran , Binghua Chang , Wei You , Qiyue Wang , Jun Ye , Yan Shen

{"title":"A spatiotemporal selective bioinspired hybrid system engineered for preventing post-thrombolysis recurrence by inhibiting the ferroptosis pathway and reprogramming macrophages","authors":"Tianjiao Hao , Bin Gao , Yuanyuan Zhou , Chang Liu , Chuanjiang Ran , Binghua Chang , Wei You , Qiyue Wang , Jun Ye , Yan Shen","doi":"10.1016/j.apsb.2026.01.014","DOIUrl":"10.1016/j.apsb.2026.01.014","url":null,"abstract":"<div><div>Cardiovascular diseases induced by arterial thrombosis, such as myocardial infarction and ischemic stroke, have gradually emerged as critical threats to human life and health. Sequentially targeted delivery systems are highly desired to be developed to improve the delivery of thrombolytics and anti-inflammatory medications to the site of the thrombus, respectively, to pursue a maximized combinational effect. Herein, we developed a probiotic-platelet hybrid vesicle-targeted drug delivery system (Fer-1@PLevs-C&U) to achieve sequential anti-thrombolytic delivery against thrombus and prevent its recurrence. The hybrid vesicles (PLevs) were prepared by mixing platelet membrane with <em>Lactobacillus</em> <em>plantarum</em>-derived bacterial extracellular vesicles (Levs) and further decorated with DSPE-PEG<sub>2000</sub>-CREKA, achieving “point-to-point” multi-covalent targeting of thrombus components. After targeted localization to the arterial thrombotic site, Fer-1@PLevs-C&U gradually releases the thrombolytic drug urokinase-type plasminogen activator (UPA) and Ferroptosis inhibitor (Fer-1) to facilitate thrombus dissolution and regulate the inflammatory microenvironment. By enhancing the eNOS expression and reducing the secretion of inflammatory factors TNF-<em>α</em> and IL-6, Fer-1@PLevs-C&U significantly reduced the inflammatory microenvironment and inhibited recurrent thrombus. Therefore, Fer-1@PLevs-C&U constitutes a novel biomimetic drug delivery platform with promising therapeutic potential and practical applicability.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 4","pages":"Pages 2570-2586"},"PeriodicalIF":14.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147381906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advanced oral drug delivery systems: Current challenges and emerging technologies 先进的口服给药系统：当前的挑战和新兴技术

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-04-01 Epub Date: 2025-12-03 DOI: 10.1016/j.apsb.2025.11.036

Satomi Onoue, Kohei Yamada, Hideyuki Sato

{"title":"Advanced oral drug delivery systems: Current challenges and emerging technologies","authors":"Satomi Onoue, Kohei Yamada, Hideyuki Sato","doi":"10.1016/j.apsb.2025.11.036","DOIUrl":"10.1016/j.apsb.2025.11.036","url":null,"abstract":"<div><div>Oral dosage is the most commonly used and preferred method of drug administration due to its several advantages, including non-invasiveness, patient adherence, and ease of use. However, oral bioavailability can be influenced by several factors, such as drug solubility and mucosal permeability in the gastrointestinal tract, sometimes leading to poor and/or inconsistent absorption. In particular, low aqueous solubility presents a significant challenge in achieving adequate oral bioavailability and therapeutic effectiveness for many pharmaceutical compounds. Attempts to overcome these limitations have focused on deeper understanding of the physicochemical, biochemical, and biological barriers that limit overall drug bioavailability. To ensure better and stable pharmacokinetic behavior of orally administered drugs, various formulation strategies have been developed to enhance solubility, dissolution rate, membrane permeability, and overall oral bioavailability. This review article explores recent advancements in formulation techniques aimed at improving the biopharmaceutical properties of orally administered drugs. The challenges and development aspects of oral dosage forms are also addressed.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 4","pages":"Pages 2029-2042"},"PeriodicalIF":14.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147706750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances of microneedle technology for the treatment of autoimmune diseases 微针技术在自身免疫性疾病治疗中的进展

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-04-01 Epub Date: 2026-01-10 DOI: 10.1016/j.apsb.2026.01.003

Ying Chen , Yanping Fu , Xinyu Wen , Minglong Chen , Linghui Dian , Tingting Peng , Chuanbin Wu , Chao Lu , Guilan Quan

{"title":"Advances of microneedle technology for the treatment of autoimmune diseases","authors":"Ying Chen , Yanping Fu , Xinyu Wen , Minglong Chen , Linghui Dian , Tingting Peng , Chuanbin Wu , Chao Lu , Guilan Quan","doi":"10.1016/j.apsb.2026.01.003","DOIUrl":"10.1016/j.apsb.2026.01.003","url":null,"abstract":"<div><div>Autoimmune diseases are characterized by an aberrant immune response directed against the body's own components, leading to immune dysfunction and loss of tolerance. This ultimately results in tissue damage and organ impairment. Despite the availability of a range of pharmacological agents for the treatment of autoimmune diseases, numerous challenges still remain. These include reduced bioavailability, first-pass metabolism, severe adverse effects, and low patient compliance associated with oral or injectable routes of administration. Microneedles (MNs) based delivery systems offer a promising alternative for transdermal drug administration, as they can circumvent the aforementioned limitations <em>via</em> the generation of microchannels in the skin in a minimally invasive manner with low pain. This review examines the applications and recent advances in MN systems for treating autoimmune diseases, focusing on six key areas: an overview of autoimmune diseases, current treatment modalities, an introduction to MNs, advantages of MNs for autoimmune disease treatment, advancements in MN-mediated therapies for diverse autoimmune diseases, and relevant MN technologies currently undergoing clinical trials. Additionally, it considers the prospective future advancements of MN systems in the management of autoimmune diseases.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 4","pages":"Pages 2232-2249"},"PeriodicalIF":14.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147706758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Crystal engineering for poorly water-soluble drugs: From design to applications 水溶性差药物的晶体工程：从设计到应用

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-04-01 Epub Date: 2025-12-05 DOI: 10.1016/j.apsb.2025.12.003

An Chen, Yayun Peng, Zhuangzhuang Chen, Yi Lu, Minshan Guo, Ting Cai

{"title":"Crystal engineering for poorly water-soluble drugs: From design to applications","authors":"An Chen, Yayun Peng, Zhuangzhuang Chen, Yi Lu, Minshan Guo, Ting Cai","doi":"10.1016/j.apsb.2025.12.003","DOIUrl":"10.1016/j.apsb.2025.12.003","url":null,"abstract":"<div><div>The limited aqueous solubility of active pharmaceutical ingredients (APIs) remains a major challenge in drug development, severely compromising clinical performance. Crystal engineering has emerged as a powerful and versatile approach to address this issue by rationally designing API crystal structures through precise control of intermolecular interactions, thereby enhancing solubility, dissolution rates, and ultimately bioavailability. This review systematically summarizes recent advances in crystal engineering strategies for poorly water-soluble drugs, including polymorphs, cocrystals, solvates/hydrates, nanocrystals, organic framework solids, solid solutions, liquid crystals, amorphous solids, and salts. Additionally, key challenges in translational applications are discussed, including structure-property relationship, AI-driven computational modeling, <em>in vitro</em>–<em>in vivo</em> correlation establishment, and advanced crystallization techniques. The review aims to provide strategic insights of crystal engineering for overcoming solubility barriers in next-generation drug formulations.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 4","pages":"Pages 1848-1882"},"PeriodicalIF":14.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147706760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification of HMGB1 as a target of 3-O-benzoyl-20-deoxyingenol in NSCLC therapy using integrated ABPP and SIP HMGB1作为3- o -苯甲酰-20-脱氧辛醇在ABPP和SIP联合治疗NSCLC中的靶标的鉴定

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-04-01 Epub Date: 2026-02-02 DOI: 10.1016/j.apsb.2026.01.043

Yaxu Wang , Yan Liu , Yuan Zhuang , Wennan Luo , Lu Pan , Liwei Gu , Jigang Wang , Qingbo Liu , Shao-Jiang Song

引用次数: 0

Engineered apoptotic vesicle mimetics with tunable “eat-me” signaling precisely regulate tumor-associated macrophages for potentiating cancer immunotherapy 具有可调“吃我”信号的工程凋亡囊泡模拟物精确调节肿瘤相关巨噬细胞，以增强癌症免疫治疗

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-04-01 Epub Date: 2025-11-29 DOI: 10.1016/j.apsb.2025.11.032

Yu Liu , Chunbai Xiang , Yeneng Dai , Chao Li , Michael N. Okeke , Ting Jiang , Xing Yang , Yehuda G. Assaraf , Kai Miao , Yue Wang , Zhiwei Zhang , Duo Zhang , Yaping Li , Ping Gong , Qi Zhao

{"title":"Engineered apoptotic vesicle mimetics with tunable “eat-me” signaling precisely regulate tumor-associated macrophages for potentiating cancer immunotherapy","authors":"Yu Liu , Chunbai Xiang , Yeneng Dai , Chao Li , Michael N. Okeke , Ting Jiang , Xing Yang , Yehuda G. Assaraf , Kai Miao , Yue Wang , Zhiwei Zhang , Duo Zhang , Yaping Li , Ping Gong , Qi Zhao","doi":"10.1016/j.apsb.2025.11.032","DOIUrl":"10.1016/j.apsb.2025.11.032","url":null,"abstract":"<div><div>Repolarizing immunosuppressive M2-phenotype tumor-associated macrophages (TAMs) and blocking the CD47/SIRP<em>α</em> axis are promising strategies to enhance cancer immunotherapy. However, non-selective disruption of macrophage phenotypic balance and CD47/SIRP<em>α</em> signaling can lead to immune-related side effects. To address this, we develop a smart biomimetic nanoparticle (PARM) loaded with R848 and manganese ions (Mn<sup>2+</sup>). PARM is coated with an apoptotic vesicle membrane and a pH-sensitive PEG corona, enabling targeted delivery to TAMs in the acidic tumor microenvironment (TME). The PEG corona protects the nanoparticle from uptake during circulation and sheds in the TME, exposing the apoptotic vesicle membrane. This triggers specific recognition and uptake by TAMs <em>via</em> the “eat-me” signal. R848 and Mn<sup>2+</sup> repolarize TAMs into a pro-inflammatory phenotype, while the activation of cGAS–STING pathway by Mn<sup>2+</sup> reduces SIRP<em>α</em> expression and enhances TAM phagocytosis. <em>In vivo</em> studies demonstrate that PARM remodels the immunosuppressive TME by repolarizing TAMs and promoting CD8<sup>+</sup> T cell infiltration. This leads to significant inhibition of tumor growth and metastasis. These findings highlight the multifaceted role of the cGAS–STING pathway in TAM modulation and present a novel strategy for enhancing macrophage-based cancer immunotherapy.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 4","pages":"Pages 2498-2512"},"PeriodicalIF":14.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147331860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inhaled nucleic acid delivery systems for the treatment of pulmonary interstitial diseases: Challenges and opportunities 吸入式核酸输送系统治疗肺间质性疾病：挑战与机遇

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-04-01 Epub Date: 2026-01-06 DOI: 10.1016/j.apsb.2025.12.047

Jingwen Dong , Jiahui Chen , Junmei Mu , Yinuo Fan, Jinsu Wang, Qiyan Zhang, Lin Zhang, Zhanwei Zhou, Minjie Sun

{"title":"Inhaled nucleic acid delivery systems for the treatment of pulmonary interstitial diseases: Challenges and opportunities","authors":"Jingwen Dong , Jiahui Chen , Junmei Mu , Yinuo Fan, Jinsu Wang, Qiyan Zhang, Lin Zhang, Zhanwei Zhou, Minjie Sun","doi":"10.1016/j.apsb.2025.12.047","DOIUrl":"10.1016/j.apsb.2025.12.047","url":null,"abstract":"<div><div>The treatment of interstitial lung diseases (ILDs) was important to reduce the inflammation or fibrosis within the interstitial space. In recent years, a variety of undruggable ILDs targets were emerged for anti-inflammation and anti-fibrosis therapy. The development of RNA delivery system provided the potential for undruggable targets to the lung <em>via</em> inhalation. However, the RNA delivery systems still faced the challenges, including the protection of the stability of RNA platform, increasing the effective delivery to the targeted cells, and selective escaping of RNA molecules into the cytoplasm. In this review, we first summarized the physiological and biological barriers of RNA inhaled platform. Subsequently, the progress of inhaled RNA delivery system and their therapeutic efficiency have been systematically addressed for the application of ILDs. Finally, in the design of an inhaled RNA delivery system, key factors needed to consider and perspectives are discussed.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 4","pages":"Pages 2093-2118"},"PeriodicalIF":14.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147706207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Self-assembled nanoplatforms for cancer immunotherapy: Principles, progress and perspectives 肿瘤免疫治疗的自组装纳米平台：原理、进展与展望

IF 14.6 1区医学

Acta Pharmaceutica Sinica. B Pub Date : 2026-04-01 Epub Date: 2025-06-23 DOI: 10.1016/j.apsb.2025.06.011

Wenfei Xu , Shuxuan Zhu , Zhaogang Sun , Jun Ye , Hongqian Chu

{"title":"Self-assembled nanoplatforms for cancer immunotherapy: Principles, progress and perspectives","authors":"Wenfei Xu , Shuxuan Zhu , Zhaogang Sun , Jun Ye , Hongqian Chu","doi":"10.1016/j.apsb.2025.06.011","DOIUrl":"10.1016/j.apsb.2025.06.011","url":null,"abstract":"<div><div>Cancer immunotherapy is an innovative treatment approach that leverages the immune system's ability to identify and attack tumor cells. Its goal is to initiate or re-establish the tumor–immune cycle. However, challenges such as limited response rates and adverse immune responses have hindered the further application and advancement of this therapy. Recent progress in nanomedicine, particularly in self-assembled nanomaterials, has attracted significant attention due to their excellent physical and chemical properties. Self-assembled nanoplatforms can be designed to selectively deliver immunoadjuvants, therapeutic drugs, photosensitizers, and sonosensitizers, overcoming the limitations of traditional monotherapies. By utilizing these self-assembled nanoplatforms to synergistically combine cancer immunotherapy with photodynamic therapy (PDT), photothermal therapy (PTT), radiotherapy (RT), and sonodynamic therapy (SDT), it becomes possible to amplify and enhance the immune responses elicited by these localized treatments, thus offering new strategies for cancer therapy. In this review, we discussed various immunotherapy platforms based on the self-assembly of nucleic acids, peptides and proteins, metals, and supramolecules. We also highlight the significant research advancements over the past three years in the use of self-assembled nanomaterials for combination therapies centered on immunotherapy, aiming to provide valuable insights and references for ongoing tumor therapy research.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 4","pages":"Pages 2196-2231"},"PeriodicalIF":14.6,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147706267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0